Comments
Shares of Ind-Swift Laboratories gained as much as 10 per cent on Tuesday on the announcement that it is all set to commercially launch its key API - Fexofenadine, an AntiHistamine drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
The company has tied up with a reputed generic player in the USA, which had filed the ANDA using the IndSwift Laboratories Limited DMF. The company has received commercial orders, and the supplies are beginning from the current quarter.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.